Roche Pharmaceutical Development and Sales Overview
Roche
Tecentriq (atezolizumab, RG7446)
Anti-PD-L1 cancer immunotherapy - lung cancer
Indication
1L maintenance extensive-stage SCLC
2L NSCLC previously treated with an immune checkpoint inhibitor
Phase/study
# of patients
Design
Primary endpoint
Phase III
IMforte1
N=450
■ ARM A: Platinum-etoposide + Tecentriq followed by maintenance
Tecentriq plus lurbinectedin
■ ARM B: Platinum-etoposide + Tecentriq followed by maintenance
Tecentriq
Progression-free survival and overall survival
Status
CT Identifier
FPI Q4 2021
NCT05091567
¹In collaboration with Jazz Pharma, 2In collaboration with Exelixis
NSCLC=non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1; SCLC-small cell lung cancer
■
Phase III
CONTACT-012
N=366
ARM A: Tecentriq plus cabozantinib
ARM B: Docetaxel
Overall survival
☐
FPI Q3 2020
■
Recruitment completed Q4 2021
NCT04471428
67
OncologyView entire presentation